Data regarding the impact of COCs containing 35 μg ethinylestradiol (EE) and 2 mg cyproterone acetate (CPA) on CRP levels of PCOS patients after 3-6 months of use were extracted from eleven articles, which were published in peer-reviewed journals between 2003 and 2016 [5, 16–25]. Here, CRP is linked to polycystic ovary syndrome.